NIH Weekly Funding Opportunities and Policy Notices
Notice NOT-HL-24-035 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-NR-25-002 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) invites applications from multidisciplinary teams of experts in firearm injury prevention research across departments and institutions to develop and provide research resources and support to build capacity among United States (U.S.) nurse researchers for rigorous, high-impact research in firearm injury prevention aligned with the NINR mission and scientific framework. These R24 awards are intended to: 1) build research resources that respond to the specific needs of the nurse researcher community; 2) train and attract new nurse researchers into the field; 3) support potential pilot project programs to accelerate research progress toward an NIH award; and 4) advance firearm injury prevention research infused with a social determinants and health equity perspective.
Funding Opportunity RFA-DA-26-017 from the NIH Guide for Grants and Contracts. This notice of funding opportunity (NOFO) invites Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) proposing research and development of medical devices specifically indicated for pediatric population (i.e., 0-21 years old, as defined by the FDA Center for Devices and Radiological Health) affected by substance use and addiction.
Funding Opportunity RFA-DA-26-016 from the NIH Guide for Grants and Contracts. This notice of funding opportunity (NOFO) invites Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) proposing research and development of medical devices specifically indicated for pediatric population (i.e., 0-21 years old, as defined by the FDA Center for Devices and Radiological Health) affected by substance use and addiction.
Funding Opportunity PAR-25-261 from the NIH Guide for Grants and Contracts. The NIDA Avant-Garde Award Program for HIV/AIDS Research supports individual scientists of exceptional creativity who propose high-impact research that will open new areas of HIV/AIDS research relevant to drug abuse and/or lead to new avenues for prevention and treatment of HIV/AIDS among drug abusers. The term avant-garde is used to describe highly innovative approaches that have the potential to be transformative. The proposed research should reflect approaches and ideas that are substantially different from those already being pursued by the investigator or others and should support the NIH HIV/AIDS Research Priorities https://grants.nih.gov/grants/guide/notice-files/NOT-OD-20-018.html. The NIDA Avant-Garde award supports innovative, basic research that may lead to improved preventive interventions or therapies; creative, new strategies to prevent disease transmission; novel approaches to improve disease outcomes; and creative approaches to eradicating HIV or improving the lives of those living with HIV.
Funding Opportunity RFA-MH-26-111 from the NIH Guide for Grants and Contracts. Eradicating latent reservoirs of HIV-1 within the body and achieving a sterilizing or functional cure have become priority areas in the AIDS field and NIH AIDS programs across many Institutes and Centers, including NIMH. In addition understanding the mechanisms of HIV- associated co-morbidities in the setting of effective anti-retroviral therapy (ART) is a major topic of interest in the field. HIV Associated CNS (central nervous system) co-morbidities continue to exist despite excellent virologic control in this compartment. HIV persistence and neuroinflammation also continues to observed in the CNS in the setting of ART. HIV targets the CNS early in infection, and HIV-infected individuals suffer from mild forms of neurological impairments even under antiretroviral therapy (ART). CD4+ T cells and monocytes mediate HIV entry into the brain and constitute a source for HIV persistence and neuronal damage. CD8+ T cells are also massively recruited in the CNS in acute infection to control viral replication.
Funding Opportunity RFA-MH-26-110 from the NIH Guide for Grants and Contracts. Eradicating latent reservoirs of HIV-1 within the body and achieving a sterilizing or functional cure have become priority areas in the AIDS field and NIH AIDS programs across many Institutes and Centers, including NIMH. In addition understanding the mechanisms of HIV- associated co-morbidities in the setting of effective anti-retroviral therapy (ART) is a major topic of interest in the field. HIV Associated CNS (central nervous system) co-morbidities continue to exist despite excellent virologic control in this compartment. HIV persistence and neuroinflammation also continues to observed in the CNS in the setting of ART. HIV targets the CNS early in infection, and HIV-infected individuals suffer from mild forms of neurological impairments even under antiretroviral therapy (ART). CD4+ T cells and monocytes mediate HIV entry into the brain and constitute a source for HIV persistence and neuronal damage. CD8+ T cells are also massively recruited in the CNS in acute infection to control viral replication.
Notice NOT-MH-25-076 from the NIH Guide for Grants and Contracts
Notice NOT-MH-25-075 from the NIH Guide for Grants and Contracts
Notice NOT-AI-24-084 from the NIH Guide for Grants and Contracts
Notice NOT-GM-25-009 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-26-001 from the NIH Guide for Grants and Contracts. The Office of Disease Prevention (ODP) and participating National Institutes of Health (NIH) Institutes, Centers, and Offices (ICOs) are issuing this notice of funding opportunity (NOFO) seeking applications to test innovative approaches to implementing SBIRT/P for alcohol, tobacco, and other drugs (ATOD) use and misuse in adult populations that experience health disparities. SBIRT/P, (a term used for purposes of this funding announcement), involves screening individuals for risk of ATOD use and misuse, briefly intervening with a conversation about harmful substance use, and referring individuals for treatment or preventive services, as needed. Proposed research should include prospective tests of SBIRT/P and should leverage collaborations with healthcare and community partners. Specific research interests of participating NIH ICOs are detailed within.
Notice NOT-OD-25-035 from the NIH Guide for Grants and Contracts
Notice NOT-AI-24-081 from the NIH Guide for Grants and Contracts
Notice NOT-DA-24-052 from the NIH Guide for Grants and Contracts
Notice NOT-DA-24-051 from the NIH Guide for Grants and Contracts
Notice NOT-NR-25-007 from the NIH Guide for Grants and Contracts
Notice NOT-NR-25-006 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-25-035 from the NIH Guide for Grants and Contracts. SRF Reissue: The overall goal of this notice of funding opportunity (NOFO) is to identify, in animals, in vivo neurophysiological and behavioral measures for use as assays in the early screening phase of treatment development. The NOFO will support efforts to optimize and evaluate measures of neurophysiological and behavioral processes that may serve as surrogate markers of neural processes of clinical interest based on available knowledge of the neurobiology of mental illnesses. The screening assays thus developed from this NOFO are expected to build upon systems neurobiology and clinical neuroscience to enhance the scientific value of preclinical animal data contributing to a therapeutic development pipeline by assessing the impact of therapeutic targets and treatment candidates on neurobiological mechanisms of clinical relevance to mental illnesses.
Funding Opportunity PAR-25-034 from the NIH Guide for Grants and Contracts. SRF Reissue: The overall goal of this initiative is to identify neurophysiological measures potential assays for treatment development research. The Notice of Funding Opportunity (NOFO) will support efforts to optimize and evaluate measures of neurophysiological processes that are disrupted within or across mental disorders in both healthy humans and in another species relevant to the therapeutic development pipeline. The initiative will support initial proof of concept studies aimed at identifying measures for potential development as preclinical assays for evaluating potential new drug and device therapies and their targets. Data will also reveal assay measures where the performance between preclinical animal species and humans is dissimilar, thus establishing a firm basis for limiting speculative extrapolations of preclinical animal findings to humans. The ultimate practical goal of this NOFO is to improve the efficiency of the therapeutic development process by identifying coherence of measures and inconsistencies between the preclinical screening pipeline and clinical evaluation of new treatment candidates and thereby hasten the development of more effective treatments for mental disorders.